

1 **City-wide school-located influenza vaccination: a retrospective cohort study**

2
3 Jade Benjamin-Chung^{1,2}, Benjamin F. Arnold³, Kunal Mishra², Chris J. Kennedy², Anna Nguyen²,
4 Nolan N. Pokpongkiat², Stephanie Djajadi², Anmol Seth², Nicola P. Klein⁵, Alan E. Hubbard²,
5 Arthur Reingold², John M. Colford, Jr.²

6
7 ¹ Department of Epidemiology & Population Health, Stanford University, Stanford, CA, United
8 States

9 ² Division of Epidemiology & Biostatistics, University of California, Berkeley, CA, United States

10 ³ Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, United
11 States

12 ⁴ Department of Ophthalmology, University of California, San Francisco, San Francisco, CA,
13 United States

14 ⁵ Kaiser Permanente Vaccine Study Center, Oakland, CA, United States

15

16 **Key words:** influenza, influenza vaccination, school-located influenza vaccination

17

18 **Corresponding author:** Jade Benjamin-Chung, jadebc@stanford.edu, 259 Campus Drive
19 HRP Redwood Building T152A, Stanford University, Stanford, CA 94305

20

21 **Abstract**

22

23 **Background:** We measured the effectiveness of a city-wide school-located influenza vaccination
24 (SLIV) program implemented in over 102 elementary schools in Oakland, California.

25

26 **Methods:** We conducted a retrospective cohort study among Kaiser Permanente Northern
27 California (KPNC) members of all ages residing in either the intervention or a multivariate-
28 matched comparison site from September 2011 - August 2017. Outcomes included medically
29 attended acute respiratory illness (MAARI), influenza hospitalization, and Oseltamivir
30 prescriptions. We estimated difference-in-differences (DIDs) in 2014-15, 2015-16, and 2016-17
31 using generalized linear models and adjusted for race, ethnicity, age, sex, health plan, and
32 language.

33

34 **Results:** Pre-intervention member characteristics were similar between sites. Among school-
35 aged children, SLIV was associated with lower Oseltamivir prescriptions per 1,000 (DIDs: -3.5
36 (95% CI -5.5, -1.5) in 2015-16; -4.0 (95% CI -6.5, -1.6) in 2016-17) but not with other outcomes.
37 SLIV was associated with lower MAARI per 1,000 in adults 65+ years (2014-15: -13.2, 95% CI
38 -23.2, -3.2; 2015-16: -21.5, 95% CI -31.1, -11.9; 2016-17: -13.0, 95% CI -23.2, -2.9). There were
39 few significant associations with other outcomes among adults.

40

41 **Conclusions:** A city-wide SLIV intervention was associated with lower Oseltamivir prescriptions
42 in school-aged children and lower MAARI among people over 65 years, suggesting possible
43 indirect effects of SLIV among older adults.

44

45 Introduction

46 In the United States, seasonal influenza has been responsible for 140,000 – 590,000
47 hospitalizations and 12,000 – 61,000 deaths annually since 2010 [1]. Children are responsible
48 for the majority of influenza transmission, and mathematical models suggest that vaccinating
49 50% – 70% of school-aged children for influenza can produce herd immunity [2].

50 School-located influenza vaccination (SLIV) interventions may increase vaccine coverage
51 among schoolchildren and reduce influenza transmission community-wide [3]. SLIV is
52 associated with higher influenza vaccination coverage [4–13] and lower medically attended
53 acute respiratory illness (MAARI) [14], influenza-like illness [4] and laboratory-confirmed
54 influenza [14,15] in schoolchildren. Some studies have reported indirect effects of SLIV among
55 non-school aged individuals, while others found none [7,8,14,16–20]. With the exception of one
56 study [4], prior SLIV evaluations have measured health outcomes using observational designs
57 that did not rigorously account for systematic differences between intervention and
58 comparison sites prior to intervention [5–8,13–20].

59 We previously reported the findings from a matched cohort study of a city-wide SLIV
60 program called Shoo the Flu that was implemented in a diverse, primarily low-income
61 population in Oakland, California [21]. The initial evaluation found higher vaccination coverage
62 and lower influenza hospitalization among non-elementary school aged individuals in the
63 intervention site.

64 Here, we report the results of a retrospective cohort study to measure associations
65 between Shoo the Flu program on additional outcomes, including MAARI and Oseltamivir
66 prescriptions, among Kaiser Permanente Northern California (KPNC) members residing within

67 either the intervention or a matched comparison area. Using data from 2011 to 2017, we
68 estimated associations with SLIV among school-aged individuals and assessed potential indirect
69 effects in other age groups.

70 **Methods**

71 SLIV intervention

72 This study evaluated the Shoo the Flu intervention (www.shootheflu.org), which has
73 delivered free influenza vaccinations to schools in Oakland, California since 2014. The
74 intervention was delivered to children in all public and charter elementary schools in Oakland
75 Unified School District (OUSD, the “intervention district”) and offered to all other charter and
76 private pre-schools and elementary schools in Oakland. OUSD has a diverse population of over
77 26,000 elementary school students, and >70% are low-income. From 2014-2017, Shoo the Flu
78 vaccinated 7,502 – 10,106 students annually (22 – 28% of eligible students) in 102-138 schools.
79 Each influenza season, 23-24% of intervention participants reported KPNC health plan
80 membership. Additional intervention details are in the Supplement 1.

81 Study setting and population

82 KPNC is an integrated healthcare system that delivers care at 46 medical clinics and 21
83 hospitals operated by KPNC to approximately 4 million members. Members comprise at least
84 30% of the population and are representative of the race, ethnicity, and socioeconomic
85 distribution of Northern California, although very low-income individuals are under-
86 represented. Health care visits, diagnoses, prescriptions, immunizations, and laboratory results
87 are captured in KPNC’s electronic medical record. Vaccines are offered free of charge to
88 members, and the date, injection site, and vaccine brand, lot, and dose of each vaccination at

89 KPNC are recorded. Whether to test patients for influenza A or B using polymerase chain
90 reaction is at the discretion of KPNC clinicians.

91 All KPNC members who resided in the catchment areas of the intervention and
92 comparison districts from September 1, 2011 - August 31, 2017 and had no more than a one-
93 month gap in KPNC membership for each influenza season during the study period were
94 included in this study.

95 Vaccines

96 In 2014-15 and 2015-16, the intervention provided the live attenuated influenza vaccine
97 (LAIV) to students [22,23]. Students with LAIV contraindications were offered the trivalent
98 inactivated injectable influenza vaccine (IIV3), as were staff and teachers. Because LAIV
99 effectiveness in children was low in 2014-15 and 2015-16 [24–26], the intervention offered IIV4
100 to all participants following the Advisory Committee on Immunization Practices’
101 recommendation to use IIV for all children in 2016-17 [25].

102 Study design

103 We conducted a retrospective cohort study of KPNC health plan members who lived in
104 the catchment areas of the intervention district and a comparison district (West Contra Costa
105 Unified School District [WCCUSD]). We identified the comparison school district using a genetic
106 multivariate matching algorithm [27] to pair-match public elementary schools in the
107 intervention district and each candidate comparison district using pre-intervention school-level
108 characteristics (additional details in Supplement 2); detailed methods are available elsewhere
109 [21]. We selected WCCUSD as the comparison site because it had the smallest average
110 generalized Mahalanobis distance between paired schools [27].

111 Program data

112 KPNC electronic medical records did not include records for vaccinations administered
113 at locations other than KPNC. We therefore estimated the number of vaccinations delivered by
114 the program to KPNC members using data from the Shoo the Flu program, which tracks
115 vaccination counts using the number of vaccination consent forms collected from the parents
116 each year. Consent forms included information about insurance provider (e.g., KPNC or other
117 provider), allowing us to estimate the number of children vaccinated by Shoo the Flu who were
118 KPNC members.

119 Population and school district data

120 We obtained demographic information about the general population in study sites from
121 the U.S. 2010 Census using zip codes that overlapped with the intervention and comparison
122 school districts. We also obtained data about school district populations from the California
123 Department of Education for these zip codes for 2013.

124 Outcomes

125 Outcomes included medically attended acute respiratory illness (MAARI) (see
126 Supplement Table 1 for ICD-9 and ICD-10 codes), laboratory-confirmed influenza among tested
127 individuals, influenza hospitalization, and filled Oseltamivir prescriptions. Individuals
128 hospitalized with any of the following ICD-9-CM codes for otitis media and sinusitis (381–383,
129 461x), upper respiratory tract illness (79x, 460, 462–463, 465, 487.1), and lower respiratory
130 tract illness (464x, 466x, 480x–487.0, 490x–496x, 510x–513x, 515x–516x, 518x, and 786.1) were
131 classified as having an influenza hospitalization. We defined laboratory-confirmed influenza as a
132 positive result from RT-PCR influenza diagnostic test.

133 Definition of influenza season

134 We defined influenza season based on the percentage of medical visits for influenza-like
135 illness in California using data from the California Department of Public Health. Influenza season
136 started after two consecutive weeks in which the percentage of medical visits for influenza-like
137 illness was greater than or equal to 2%; it ended after two consecutive weeks with a percentage
138 under 2%.

139 Statistical analysis

140 This study's pre-analysis plan and replication scripts are available at <https://osf.io/rtsf2/>.

141 We defined the cumulative incidence as the proportion of individuals with at least one
142 outcome event in each season. We restricted analyses to influenza season, when the
143 intervention would be expected to affect influenza-related outcomes. Our primary pre-
144 specified parameter was mean difference-in-differences (DIDs) that compared the difference in
145 cumulative incidence during influenza season to that in three seasons prior to the intervention
146 (2011-2014) in each study group (the "pre-intervention DID"). Pre-intervention monthly
147 incidences of each outcome were consistent with the equal trends assumption (Supplement
148 Figure 2). DIDs remove time-invariant confounding but may be subject to time-dependent
149 confounding [28]. To account for this, we conducted a post-hoc alternative "pre-season DID"
150 analysis that compared the incidence in each influenza season to that in the period immediately
151 preceding each season (May – September). While the pre-season DID does not account for pre-
152 intervention differences, it is less subject to time-dependent confounding than the pre-
153 intervention DID.

154 Models adjusted for available potential confounders with at least 5% prevalence in each
155 analysis; these included race, ethnicity, sex, mediCAL, subsidized KPNC health plan (proxy for
156 low socio-economic status), and primary language spoken. Enrollment in mediCAL or a
157 subsidized KPNC health plan varied by season; other variables were static. To minimize
158 empirical positivity violations from sparse data [29], we fit models only if the number of
159 outcome events per variable was ≥ 10 and only fit adjusted models if the number of
160 observations within age, site, and outcome strata was ≥ 30 [30]. We estimated 95% confidence
161 intervals using robust standard errors [31] to account for clustering at the household level.
162 Additional minor deviations from the plan are noted in Supplement 3, and additional analysis
163 details are in Supplement 4.

164 We stratified estimates by pre-specified age groups (0-4, 5-12, 13-17, 18-64, and 65+
165 years). Estimates among children 5-12 years represent “total effects” (including intervention
166 participants and non-participants) and estimates in other age groups represent “indirect effects”
167 among non-participants (Supplement Figure 1) [32]. Per our pre-analysis plan, we also stratified
168 estimates by individual vaccination status.

169 We performed a sensitivity analysis using alternative influenza seasons with influenza-
170 like-illness thresholds of 2.5% and 3% and the CDC influenza season definition (Week 40 to
171 Week 20 of the following year).

172 We pre-specified two negative control analyses to detect residual confounding or
173 selection bias [33,34]. First, we repeated our primary analysis with outcomes we did not expect
174 SLIV to affect (medically attended diarrhea and medically attended gastrointestinal illness)

175 [33,34]. We conducted a negative control time period analysis restricting to weeks outside
176 influenza season.

177 Ethical statement

178 This study was approved by the Committee for the Protection of Human Subjects at the
179 University of California, Berkeley (Protocol # 2017-03-9741) and the KPNC Institutional Review
180 Board (Protocol #CN-16-2825).

181 **Results**

182 Pre-intervention characteristics

183 The analyses included 175,628 to 269,266 individuals and 9,436,202 to 11,500,570
184 person-weeks of observations per calendar year from 2011 to 2017 (Supplement Table 2).
185 During the influenza season, the number of person-weeks ranged from 3,069,633 to 6,801,780
186 per year.

187 Pre-intervention characteristics were similar among individuals in the intervention and
188 comparison sites (Table 1). In the intervention site vs. the comparison site, there were fewer
189 Asian (14.2% vs. 19.3%) and Hispanic (30.5% vs. 43.0%) individuals and more Black / African
190 American (28.2% vs. 20.2%) and White individuals (35.2% vs. 29.5%). The proportion of
191 individuals enrolled in MediCAL was lower in the intervention site vs. the comparison site (4.4%
192 vs. 6.7%).

193 Characteristics were similar overall between the study population, general population
194 (all individuals residing in zip codes overlapping with the study site) and school district
195 population (Supplement Table 3). The percentage of individuals in the study population who
196 were Hispanic was lower than in the general population (31-43% vs. 39-54%). The percentage

197 of the study population whose primary language spoken was not English was also lower (12-
198 14%) than in the general population (40-47%) and school district population (38-43%).

199 Influenza vaccination

200 Among the study population, influenza vaccination coverage was lower in the
201 intervention site than the comparison site across age groups and years. Prior to the
202 intervention, vaccination coverage was also consistently lower in the intervention site than the
203 comparison site (Supplement Table 4); this difference was larger during the intervention period
204 for children 5-12 years (Supplement Figure 3). Including all vaccinations (administered by both
205 KPNC and the SLIV intervention), coverage was 8-11% higher in the intervention site than the
206 comparison site during the intervention period (Figure 1). Across all years, KPNC mostly
207 administered IIV to elementary school aged children in the study (Supplement Figure 4).

208 Cumulative incidence of influenza-related outcomes

209 The cumulative incidence of MAARI ranged from 0.14 to 0.58 per season by age and was
210 highest among children 0-4 years (Supplement Figure 5). Very few individuals were tested for
211 influenza (<1% of individuals per season), and the proportion who tested positive varied
212 substantially by age, season, and site. The incidence of influenza hospitalization was low in all
213 age groups, with the highest incidence among adults ≥ 65 years (range: 0.053 to 0.097 per
214 season). The incidence of filled Oseltamivir prescriptions ranged from 0.0007 to 0.0134 per
215 season.

216 Associations among elementary school aged children

217 Overall, the intervention was not associated with MAARI in elementary school aged
218 children except for in 2015-16, when it was associated with lower MAARI when accounting for

219 pre-season differences between sites (Figure 2, Supplement Figure 6, Supplement Table 5).
220 Among elementary school aged children, in 2016-17 the unadjusted pre-intervention DID in the
221 cumulative incidence of filled Oseltamivir prescriptions per 1,000 was -3.5 (95% CI -5.5, -1.5) in
222 2015-16 and -4.0 (95% CI -6.5, -1.6) in 2016-17; there was no association in 2014-15. These
223 associations were attenuated towards the null in the analysis accounting for pre-season
224 differences. There was no association with influenza hospitalization elementary school aged
225 children.

226 Associations among non-elementary school aged individuals

227 DIDs indicated no association between the intervention and laboratory-confirmed
228 influenza in most program years and age groups among non-elementary school aged individuals
229 (Supplement Table 5). In intervention vs. comparison sites, MAARI per 1,000 was lower among
230 adults 65 years or older when accounting for pre-intervention differences (2014-15: -13.2, 95%
231 CI -23.2, -3.2; 2015-16: -21.5, 95% CI -31.1, -11.9; 2016-17: -13.0, 95% CI -23.2, -2.9) (Figure 2).
232 When accounting for pre-season differences, DIDs indicated slightly stronger protective
233 associations with MAARI for most age groups and seasons (Supplement Figure 6). DIDs for filled
234 Oseltamivir prescriptions per 1,000 were lower among adults 18-64 years in 2016-17 (-1.6, 95%
235 CI -2.5, -0.7); results were similar when accounting for pre-season differences. DIDs indicated a
236 higher incidence of influenza hospitalization among adults 18 years or older in 2014-15 and
237 adults 18-64 years in 2015-16. Pre-season DIDs displayed a different pattern for adults:
238 associations were null for adults 18 years or older except for adults 65 years or older in 2015-16,
239 when the association was protective.

240 For all ages, the results of adjusted models were similar to those of unadjusted models
241 (Supplement Table 6). Results stratified by vaccination status were similar overall to the
242 primary analysis (Supplement Tables 7-8).

243 Negative control analyses

244 Analyses using non-influenza outcomes (medically attended diarrhea and medically
245 attended gastrointestinal illness) produced primarily null associations (Supplement Table 9).
246 Analyses restricted to weeks outside of influenza season produced almost exclusively null
247 results (Supplement Table 10).

248 Sensitivity analyses using alternative influenza season definitions

249 Results were similar when using alternative influenza season definitions (Supplement
250 Figure 7). For outcomes with sufficient data to restrict to the peak week of influenza, results
251 suggested no association with the intervention.

252 **Discussion**

253 In this three-year evaluation of a city-wide SLIV intervention, among elementary school
254 aged children, SLIV was associated with lower Oseltamivir prescriptions but not with MAARI,
255 laboratory-confirmed influenza, or influenza hospitalization. We found some evidence of
256 indirect effects in non-elementary school aged individuals: SLIV was associated with lower
257 MAARI among adults 65 years or older and lower Oseltamivir prescriptions among pre-school
258 children in 2015-16.

259 Some prior observational studies of SLIV programs have also reported indirect effects of
260 SLIV on MAARI and related outcomes [14,18–20], while others have reported non-significant or
261 null results [7,8,13,16,17]. These studies did not use analytic methods to account for

262 differences between intervention and comparison sites prior to intervention or outside of
263 influenza season. The one prior study that did so found no association between SLIV and
264 hospitalization among the elderly [16]. The present study included three years of pre-
265 intervention data and used a DID approach to adjust for pre-intervention differences; thus, our
266 findings likely have higher internal validity than prior observational SLIV evaluations.

267 Vaccine effectiveness varied substantially during the study period. In 2014-15 all vaccine
268 formulations had low effectiveness due to a poor strain match [24]. In 2015-16, the LAIV had
269 poor vaccine effectiveness, but the IIV was moderately effective [26]. In 2016-17, only IIV was
270 available and it was moderately effective [35]. These differences and varying vaccine coverage
271 by the SLIV intervention each year [21] contribute to heterogeneous estimates across seasons.

272 SLIV may increase vaccination coverage among children who would not otherwise be
273 vaccinated and/or shift vaccination location from doctor's offices to schools. If SLIV merely
274 shifts vaccination location, it would not be expected to reduce influenza. In this study, SLIV
275 appeared to both increase vaccination and shift vaccination location among elementary school
276 aged children. The proportion of 5-12 year-olds vaccinated by their medical provider was lower
277 in the intervention site than the comparison site, but the proportion vaccinated by KPNC or SLIV
278 combined was higher. This finding is consistent with our prior evaluation of Shoo the Flu [21]
279 and evaluations of other SLIV interventions that also increased vaccination coverage [4–13].

280 Our finding that SLIV was associated with higher influenza hospitalization in adults in
281 some years was unexpected. This finding contrasts with the prior Shoo the Flu evaluation,
282 which found that SLIV was associated with lower influenza hospitalization in non-elementary
283 age groups [21]. Other prior SLIV evaluations have had conflicting findings with regard to

284 indirect effects on hospitalization [7,8,13,16,17]. One cluster-randomized trial reported a higher
285 hospitalization rate in SLIV participants, but when stratifying by child vaccination status, the
286 finding was not significant [4]. In a post-hoc analysis accounting for pre-season differences
287 between sites, which may better account for time-dependent confounding than our primary
288 analysis, associations with hospitalization were null or protective.

289 This study is subject to several limitations. First, its observational design may be subject
290 to unmeasured confounding. In a small number of negative control outcome and time period
291 analyses, unexpected associations suggest that unmeasured confounding occurred. The DID
292 analysis controlled for time-invariant confounding [28], but unmeasured time-varying
293 confounding may have occurred. Common confounders of influenza vaccine studies are age,
294 calendar time, and health status [36]. Our analysis stratified by age and season, but baseline
295 health status was not available. Second, differences in sociodemographic characteristics
296 between the study population and the general and student populations in the study sites limit
297 the generalizability of our findings. Third, many outcomes were rare, precluding formal analyses
298 for some outcomes and limiting statistical power, which may have contributed to null findings.
299 Finally, we did not have complete vaccination information about each individual. It was not
300 possible to link data from the California Immunization Registry with KPNC member data. This
301 limitation underscores the need for more robust vaccine registries [37]. Notably, the limitations
302 of this study apply to most prior SLIV evaluations, which primarily have been observational and
303 leveraged existing data. We expect that among individuals not targeted by the SLIV intervention,
304 influenza vaccinations outside KPNC were infrequent, so this limitation is unlikely to have
305 meaningfully impacted study findings.

306 Overall, our findings bolster those of our prior evaluation of a city-wide SLIV
307 intervention. This study supports our prior finding that SLIV both increased vaccination
308 coverage and shifted vaccination location and provides additional evidence that SLIV was
309 associated with lower Oseltamivir prescriptions in school aged children and lower MAARI in
310 older adults.

311

312

313 **Funding**

314 This work was supported by a grant from the Flu Lab (<https://theflulab.org/>) to the University of
315 California, Berkeley (Grant number: 20142281; PI: AR).

316 **Acknowledgements**

317 The authors would like to acknowledge Kristin Goddard, Karen Nunley, and Berwick Chan at
318 Kaiser Permanente Northern California and Kate Holbrook at Alameda County Public Health
319 Department for their contributions to data collection.

320 NPK reports research support from Protein Science (Sanofi Pasteur) and Sanofi Pasteur for
321 unrelated influenza vaccine studies and from GlaxoSmithKline, Merck & Co, and Pfizer for
322 unrelated studies. JBC, BFA, KM, CJK, AN, NNP, SD, AS, AEH, AR, JMC report no conflicts.

323 **References**

- 324 1. Centers for Disease Control and Prevention. Burden of Influenza. 2020. Available at:
325 <https://www.cdc.gov/flu/about/burden/index.html>. Accessed 27 July 2020.
- 326 2. Longini IM. A Theoretic Framework to Consider the Effect of Immunizing Schoolchildren
327 Against Influenza: Implications for Research. *Pediatrics* **2012**; 129:S63–S67.
- 328 3. Gaglani MJ. Editorial Commentary: School-Located Influenza Vaccination: Why Worth the
329 Effort? *Clin Infect Dis* **2014**; 59:333–335.
- 330 4. King JC, Stoddard JJ, Gaglani MJ, et al. Effectiveness of School-Based Influenza Vaccination.
331 *N Engl J Med* **2006**; 355:2523–2532.

- 332 5. Davis MM, King JC, Moag L, Cummings G, Magder LS. Countywide School-Based Influenza
333 Immunization: Direct and Indirect Impact on Student Absenteeism. *Pediatrics* **2008**;
334 122:e260–e265.
- 335 6. Kjos SA, Irving SA, Meece JK, Belongia EA. Elementary School-Based Influenza Vaccination:
336 Evaluating Impact on Respiratory Illness Absenteeism and Laboratory-Confirmed Influenza.
337 *PLoS ONE* **2013**; 8:e72243.
- 338 7. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of vaccinating school age
339 children against influenza during a season with circulation of drifted influenza A and B
340 strains, England, 2014/15. *Eurosurveillance* **2015**; 20.
- 341 8. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of a new live attenuated
342 influenza vaccine programme in England: early results of a pilot in primary school-age
343 children, 2013/14 influenza season. *Eurosurveillance* **2014**; 19:20823.
- 344 9. Szilagyi PG, Schaffer S, Rand CM, et al. School-Located Influenza Vaccinations: A
345 Randomized Trial. *Pediatrics* **2016**; :e20161746.
- 346 10. Szilagyi PG, Schaffer S, Rand CM, et al. Impact of elementary school-located influenza
347 vaccinations: A stepped wedge trial across a community. *Vaccine* **2018**; 36:2861–2869.
- 348 11. Szilagyi PG, Schaffer S, Rand CM, et al. School-Located Influenza Vaccination: Do Vaccine
349 Clinics at School Raise Vaccination Rates? *J Sch Health* **2019**; 89:1004–1012.

- 350 12. Humiston SG, Schaffer SJ, Szilagyi PG, et al. Seasonal Influenza Vaccination at School: A
351 Randomized Controlled Trial. *Am J Prev Med* **2014**; 46:1–9.
- 352 13. Pebody RG, Sinnathamby MA, Warburton F, et al. Uptake and impact of vaccinating primary
353 school-age children against influenza: experiences of a live attenuated influenza vaccine
354 programme, England, 2015/16. *Eurosurveillance* **2018**; 23:1700496.
- 355 14. Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA. Direct and Indirect Effectiveness of
356 Influenza Vaccination Delivered to Children at School Preceding an Epidemic Caused by 3
357 New Influenza Virus Variants. *J Infect Dis* **2010**; 202:1626–1633.
- 358 15. Pannaraj PS, Wang H-L, Rivas H, et al. School-Located Influenza Vaccination Decreases
359 Laboratory-Confirmed Influenza and Improves School Attendance. *Clin Infect Dis* **2014**;
360 59:325–332.
- 361 16. McBean M, Hull HF, O’Connor H. Possible Herd Immunity in the Elderly Following the
362 Vaccination of School Children with Live, Attenuated Trivalent Influenza Vaccine: A Person-
363 Level Analysis. *Procedia Vaccinol* **2011**; 4:59–70.
- 364 17. Hull HF, McBean AM, Caldwell D, O’Connor H. Assessing Herd Immunity in the Elderly
365 Following the Vaccination of School Children with Live Attenuated Trivalent Influenza
366 Vaccine (LAIV): A County-Level Analysis. *Procedia Vaccinol* **2010**; 2:90–98.
- 367 18. Tran CH, Sugimoto JD, Pulliam JRC, et al. School-Located Influenza Vaccination Reduces
368 Community Risk for Influenza and Influenza-Like Illness Emergency Care Visits. *PLoS ONE*
369 **2014**; 9:e114479.

- 370 19. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related
371 illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.
372 Vaccine **2005**; 23:1540–1548.
- 373 20. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent Live Attenuated Intranasal Influenza
374 Vaccine Administered During the 2003–2004 Influenza Type A (H3N2) Outbreak Provided
375 Immediate, Direct, and Indirect Protection in Children. Pediatrics **2007**; 120:e553–e564.
- 376 21. Benjamin-Chung J, Arnold BF, Kennedy CJ, et al. Evaluation of a city-wide school-located
377 influenza vaccination program in Oakland, California with respect to vaccination coverage,
378 school absences, and laboratory-confirmed influenza: a matched cohort study. PLOS Med
379 **2020**; 17:e1003238.
- 380 22. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with
381 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) --
382 United States, 2014-15 influenza season. Morb Mortal Wkly Rep **2014**; 63:691–697.
- 383 23. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and
384 Control of Influenza with Vaccines: Recommendations of the Advisory Committee on
385 Immunization Practices, United States, 2015-16 Influenza Season. Morb Mortal Wkly Rep
386 **2015**; 64:818–825.
- 387 24. Zimmerman RK, Nowalk MP, Chung J, et al. 2014–2015 Influenza Vaccine Effectiveness in
388 the United States by Vaccine Type. Clin Infect Dis **2016**; 63:1564–1573.

- 389 25. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza
390 with Vaccines: Recommendations of the Advisory Committee on Immunization Practices —
391 United States, 2016–17 Influenza Season. *Morb Mortal Wkly Rep* **2016**; 65:1–54.
- 392 26. Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United States
393 during the 2015–2016 Season. *N Engl J Med* **2017**; 377:534–543.
- 394 27. Diamond A, Sekhon JS. Genetic Matching for Estimating Causal Effects: A General
395 Multivariate Matching Method for Achieving Balance in Observational Studies. *Rev Econ*
396 *Stat* **2013**; 95:932–945.
- 397 28. Wing C, Simon K, Bello-Gomez RA. Designing Difference in Difference Studies: Best Practices
398 for Public Health Policy Research. *Annu Rev Public Health* **2018**; 39:453–469.
- 399 29. Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ. Diagnosing and responding to
400 violations in the positivity assumption. *Stat Methods Med Res* **2010**; 21:31–54.
- 401 30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number
402 of events per variable in logistic regression analysis. *J Clin Epidemiol* **1996**; 49:1373–1379.
- 403 31. Freedman DA. On The So-Called “Huber Sandwich Estimator” and “Robust Standard Errors”.
404 *Am Stat* **2006**; 60:299–302.
- 405 32. Benjamin-Chung J, Arnold BF, Berger D, et al. Spillover effects in epidemiology: parameters,
406 study designs and methodological considerations. *Int J Epidemiol* **2018**; 47:332–347.

- 407 33. Lipsitch M, Tchetgen ET, Cohen T. Negative controls: a tool for detecting confounding and
408 bias in observational studies. *Epidemiol Camb Mass* **2010**; 21:383–388.
- 409 34. Arnold BF, Ercumen A, Benjamin-Chung J, Colford JM. Negative Controls to Detect Selection
410 Bias and Measurement Bias in Epidemiologic Studies: *Epidemiology* **2016**; 27:637–641.
- 411 35. Centers for Disease Control. Seasonal Influenza Vaccine Effectiveness, 2016-2017. 2019.
412 Available at: <https://www.cdc.gov/flu/vaccines-work/2016-2017.html>. Accessed 14 June
413 2019.
- 414 36. Ainslie KEC, Haber M, Orenstein WA. Challenges in estimating influenza vaccine
415 effectiveness. *Expert Rev Vaccines* **2019**; 18:615–628.
- 416 37. Benjamin-Chung J, Reingold A. Measuring the Success of the US COVID-19 Vaccine
417 Campaign—It’s Time to Invest in and Strengthen Immunization Information Systems. *Am J*
418 *Public Health* **2021**; :e1–e3.

419

420

421

422 **Table 1. Pre-intervention characteristics of the study population in each site**

423

	Intervention % (95% CI)	Comparison % (95% CI)
Age (years)		
Under 5	5.2 (5.1, 5.4)	5.5 (5.4, 5.7)
5-14	10.6 (10.4, 10.8)	13.5 (13.3, 13.8)
15-17	3.1 (3.0, 3.2)	4.2 (4.0, 4.3)
18-64	66.0 (65.6, 66.4)	62.2 (61.7, 62.6)
65 and over	15.0 (14.7, 15.4)	14.6 (14.1, 15.0)
Sex		
Female	53.8 (53.5, 54.0)	52.8 (52.5, 53.1)
Male	46.2 (45.9, 46.5)	47.2 (46.9, 47.5)
Race		
Asian	14.2 (13.7, 14.6)	19.3 (18.9, 19.8)
Black / African American	28.2 (27.7, 28.8)	20.2 (19.5, 20.8)
Hawaiian / Pacific Islander	0.5 (0.4, 0.5)	0.9 (0.8, 1.0)
Native American	0.4 (0.3, 0.4)	0.4 (0.4, 0.5)
Multiracial	1.2 (1.1, 1.2)	1.1 (1.0, 1.2)
White	35.2 (34.7, 35.7)	29.5 (29.0, 30.1)
Race not recorded	20.4 (19.9, 20.8)	28.5 (28.0, 29.1)
Hispanic Ethnicity ^a	30.5 (29.9, 31.2)	43.0 (42.2, 43.7)
MediCAL enrollee	4.4 (4.2, 4.6)	6.7 (6.4, 7.0)
Subsidized KPNC insurance	1.0 (0.9, 1.1)	1.5 (1.4, 1.7)
Primary language is not English ^b	12.0 (11.7, 12.4)	14.1 (13.7, 14.6)


424 Includes data for 101,761 Kaiser Permanente Northern California patients between September 1, 2013 and August 31, 2014.

425 ^a Includes data for 61,847 Kaiser Permanente Northern California with recorded Hispanic ethnicity.


426 ^b Includes data for 100,492 Kaiser Permanente Northern California with recorded primary language.

427

428



429
430 **Figure 1. Percentage of elementary school aged study population vaccinated for influenza by**
431 **Kaiser Permanente Northern California or the Shoo the Flu intervention**
432 “Vaccination by KPNC – Comparison” includes influenza vaccinations delivered by KPNC in the
433 comparison site. “Vaccination by KPNC – Intervention” includes influenza vaccinations delivered
434 by KPNC in the intervention site. “Vaccination by Shoo the Flu” includes influenza vaccinations
435 delivered by the Shoo the Flu intervention in the intervention site. The percentage vaccinated
436 for influenza does not include vaccinations that were not delivered by KPNC or Shoo the Flu.
437 The denominator is KPNC patients aged 5-12 years.
438
439



440
441 **Figure 2. Difference-in-differences accounting for pre-intervention differences**
442 Difference-in-difference in cumulative incidence of each outcome during each influenza season
443 comparing the difference in mean outcome in each district in an intervention year compared to
444 the three pre-intervention years (2011-2013). Difference-in-difference parameters remove any
445 time-invariant differences between groups (measured or unmeasured). Parameters were
446 estimated using a generalized linear model without covariate adjustment due to data sparsity.
447 Standard errors accounted for clustering at the household level. Estimates in children 5-12
448 years measure total effects and estimates in other age groups measure indirect effects.
449 Analyses were restricted to influenza season defined based the percentage of medical visits for
450 influenza-like illness in California as reported by the California Department of Public Health.
451 Influenza season started when there were at least 2 consecutive weeks in which the percentage
452 of medical visits for influenza-like illness exceeded 2%, and the season ended when there were
453 at least two consecutive weeks in which the percentage was less than or equal to 2%.